IBD Study Shows Celltrion’s Inflectra, Biosimilar of Infliximab, Is Safe and Effective

IBD Study Shows Celltrion’s Inflectra, Biosimilar of Infliximab, Is Safe and Effective
Celltrion’s Inflectra, a biosimilar version of infliximab (Remicade), is both safe and effective in patients with inflammatory bowel disease (IBD), a recent study reported at the Digestive Disease Week 2016 meeting May 21-24 in San Diego, California. The data supports the use of the drug, which was recently approved by the U.S. Food and Drug Administration (FDA), proving it to be a viable and economic option to infliximab. Biosimilars — compounds that can
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *